<DOC>
	<DOC>NCT00781391</DOC>
	<brief_summary>This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, &amp; Warfarin. The expected duration of the study is 24 months.</brief_summary>
	<brief_title>Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>21 years of age or older; male or female. Able to provide written informed consent. History of documented AF within the prior 12 months A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2 Transient atrial fibrillation secondary to other reversible disorders Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve Subjects with any contraindication for anticoagulant agents; Subjects with conditions associated with high risk of bleeding or have known or suspected hereditary or acquired bleeding disorders Females of childbearing potential including the following: Females with a history of tuballigation Females less than 2 years postmenopausal</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Systemic embolic events</keyword>
</DOC>